Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Correction to: Endorsement by Central European experts of the revised ESCEO algorithm for the management of knee osteoarthritis.

Kucharz EJ, Szántó S, Ivanova Goycheva M, Petronijević M, Šimnovec K, Domżalski M, Gallelli L, Kamenov Z, Konstantynowicz J, Radunović G, Šteňo B, Stoilov R, Stok R, Vrana R, Bruyère O, Cooper C, Reginster JY.

Rheumatol Int. 2019 Jun 20. doi: 10.1007/s00296-019-04347-z. [Epub ahead of print]

PMID:
31297562
2.

Endorsement by Central European experts of the revised ESCEO algorithm for the management of knee osteoarthritis.

Kucharz EJ, Szántó S, Ivanova Goycheva M, Petronijević M, Šimnovec K, Domżalski M, Gallelli L, Kamenov Z, Konstantynowicz J, Radunović G, Šteňo B, Stoilov R, Stok R, Vrana R, Bruyère O, Cooper C, Reginster JY.

Rheumatol Int. 2019 Jul;39(7):1117-1123. doi: 10.1007/s00296-019-04332-6. Epub 2019 May 25. Erratum in: Rheumatol Int. 2019 Jun 20;:.

PMID:
31129712
3.

Gene expression analysis of vascular pathophysiology related to anti-TNF treatment in rheumatoid arthritis.

Póliska S, Besenyei T, Végh E, Hamar A, Pusztai A, Váncsa A, Bodnár N, Szamosi S, Csumita M, Kerekes G, Szabó Z, Nagy Z, Szűcs G, Szántó S, Zahuczky G, Nagy L, Szekanecz Z.

Arthritis Res Ther. 2019 Apr 15;21(1):94. doi: 10.1186/s13075-019-1862-6.

4.

Peripheral Lymphocyte Multidrug Resistance Activity as a Predictive Tool of Biological Therapeutic Response in Rheumatoid Arthritis.

Toldi G, Batel P, Baráth S, Szerémy P, Apjok A, Filkor K, Szántó S, Szűcs G, Szamosi S, Häupl T, Grützkau A, Szekanecz Z.

J Rheumatol. 2019 Jun;46(6):572-578. doi: 10.3899/jrheum.180793. Epub 2019 Feb 1.

PMID:
30709954
5.

Autoimmune and angiogenic biomarkers in autoimmune atherosclerosis.

Balogh E, Pusztai A, Hamar A, Végh E, Szamosi S, Kerekes G, McCormick J, Biniecka M, Szántó S, Szűcs G, Nagy Z, Fearon U, Veale DJ, Szekanecz Z.

Clin Immunol. 2019 Feb;199:47-51. doi: 10.1016/j.clim.2018.12.011. Epub 2018 Dec 10.

PMID:
30543922
6.

Impact of adalimumab on clinical outcomes, healthcare resource utilization, and sick leave in patients with ankylosing spondylitis: an observational study from five Central and Eastern European countries.

Opris-Belinski D, Erdes SF, Grazio S, Šenolt L, Hojnik M, Nagy O, Marina D, Szántó S.

Drugs Context. 2018 Nov 21;7:212556. doi: 10.7573/dic.212556. eCollection 2018.

7.

[Peroral and transdermal application of non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment of regional musculoskeletal pain syndromes].

Hodinka L, Bálint G, Budai E, Géher P, Papp R, Somogyi P, Szántó S, Vereckei E.

Orv Hetil. 2017 Dec;158(Suppl 3):3-30. doi: 10.1556/650.2017.30902. Review. Hungarian.

PMID:
29307215
8.

Effects of targeted therapies on the bone in arthritides.

Szentpétery Á, Horváth Á, Gulyás K, Pethö Z, Bhattoa HP, Szántó S, Szücs G, FitzGerald O, Schett G, Szekanecz Z.

Autoimmun Rev. 2017 Mar;16(3):313-320. doi: 10.1016/j.autrev.2017.01.014. Epub 2017 Jan 31. Review.

PMID:
28159704
9.

Comparison of peripheral quantitative computed tomography forearm bone density versus DXA in rheumatoid arthritis patients and controls.

Juhász B, Gulyás K, Horváth Á, Pethő Z, Bhattoa HP, Váncsa A, Szekanecz É, Horváth C, Kocsis J, Horváth Z, Hodosi K, Szántó S, Szűcs G, Szekanecz Z.

Osteoporos Int. 2017 Apr;28(4):1271-1277. doi: 10.1007/s00198-016-3850-x. Epub 2016 Dec 10.

PMID:
27942777
10.

Improved clinical, functional and work outcomes in spondyloarthritides during real-life adalimumab treatment in central-eastern Europe.

Szántó S, Poór G, Opris D, Iaremenko O, Procházková L, Kuuse R, Nagy O, Chernyshov V, Géher P.

J Comp Eff Res. 2016 Aug;5(5):475-85. doi: 10.2217/cer-2016-0020. Epub 2016 Jul 15.

PMID:
27417564
11.

Evaluation of the immunogenicity of the 13-valent conjugated pneumococcal vaccine in rheumatoid arthritis patients treated with etanercept.

Rákóczi É, Perge B, Végh E, Csomor P, Pusztai A, Szamosi S, Bodnár N, Szántó S, Szücs G, Szekanecz Z.

Joint Bone Spine. 2016 Dec;83(6):675-679. doi: 10.1016/j.jbspin.2015.10.017. Epub 2016 Mar 16.

PMID:
26995488
12.

A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes.

Kucharz EJ, Kovalenko V, Szántó S, Bruyère O, Cooper C, Reginster JY.

Curr Med Res Opin. 2016 Jun;32(6):997-1004. doi: 10.1185/03007995.2016.1154521. Epub 2016 Feb 26. Review.

PMID:
26881468
13.

[Disease burden of psoriasis associated with psoriatic arthritis in Hungary].

Rencz F, Brodszky V, Péntek M, Balogh O, Remenyik E, Szegedi A, Holló P, Kárpáti S, Jókai H, Herszényi K, Herédi E, Szántó S, Gulácsi L.

Orv Hetil. 2014 Nov 30;155(48):1913-21. doi: 10.1556/OH.2014.30044. Hungarian.

PMID:
25417138
14.

Real-life experience with switching TNF-α inhibitors in ankylosing spondylitis.

Gulyas K, Bodnar N, Nagy Z, Szamosi S, Horvath A, Vancsa A, Vegh E, Szabo Z, Szucs G, Szekanecz Z, Szanto S.

Eur J Health Econ. 2014 May;15 Suppl 1:S93-100. doi: 10.1007/s10198-014-0598-0. Epub 2014 May 16.

PMID:
24832840
15.

Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis.

Baji P, Péntek M, Szántó S, Géher P, Gulácsi L, Balogh O, Brodszky V.

Eur J Health Econ. 2014 May;15 Suppl 1:S45-52. doi: 10.1007/s10198-014-0593-5. Epub 2014 May 16. Review.

16.

Treatment of ankylosing spondylitis with biologics and targeted physical therapy: positive effect on chest pain, diminished chest mobility, and respiratory function.

Gyurcsik Z, Bodnár N, Szekanecz Z, Szántó S.

Z Rheumatol. 2013 Dec;72(10):997-1004. doi: 10.1007/s00393-013-1240-8.

PMID:
23929243
17.

Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion.

Váncsa A, Szabó Z, Szamosi S, Bodnár N, Végh E, Gergely L, Szucs G, Szántó S, Szekanecz Z.

J Rheumatol. 2013 May;40(5):565-71. doi: 10.3899/jrheum.111488. Epub 2013 Apr 1.

PMID:
23547216
18.

Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study.

Dougados M, Braun J, Szanto S, Combe B, Geher P, Leblanc V, Logeart I.

Rheumatology (Oxford). 2012 Sep;51(9):1687-96. doi: 10.1093/rheumatology/kes125. Epub 2012 May 30.

PMID:
22653382
19.

Improvement in pain intensity, spine stiffness, and mobility during a controlled individualized physiotherapy program in ankylosing spondylitis.

Gyurcsik ZN, András A, Bodnár N, Szekanecz Z, Szántó S.

Rheumatol Int. 2012 Dec;32(12):3931-6. doi: 10.1007/s00296-011-2325-9. Epub 2011 Dec 25.

PMID:
22198694
20.
21.

Anti-mutated citrullinated vimentin (anti-MCV) and anti-65 kDa heat shock protein (anti-hsp65): new biomarkers in ankylosing spondylitis.

Bodnár N, Szekanecz Z, Prohászka Z, Kemény-Beke A, Némethné-Gyurcsik Z, Gulyás K, Lakos G, Sipka S, Szántó S.

Joint Bone Spine. 2012 Jan;79(1):63-6. doi: 10.1016/j.jbspin.2011.03.010. Epub 2011 Jun 16.

PMID:
21683641
22.

Coexistence of ankylosing spondylitis and rheumatoid arthritis in a female patient.

Baksay B, Dér A, Szekanecz Z, Szántó S, Kovács A.

Clin Rheumatol. 2011 Aug;30(8):1119-22. doi: 10.1007/s10067-011-1740-3. Epub 2011 Apr 20.

PMID:
21505766
23.

Spontaneous insertion of a b2 element in the ptpn6 gene drives a systemic autoinflammatory disease in mice resembling neutrophilic dermatosis in humans.

Nesterovitch AB, Szanto S, Gonda A, Bardos T, Kis-Toth K, Adarichev VA, Olasz K, Ghassemi-Najad S, Hoffman MD, Tharp MD, Mikecz K, Glant TT.

Am J Pathol. 2011 Apr;178(4):1701-14. doi: 10.1016/j.ajpath.2010.12.053.

24.

Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE).

Dougados M, Braun J, Szanto S, Combe B, Elbaz M, Geher P, Thabut G, Leblanc V, Logeart I.

Ann Rheum Dis. 2011 May;70(5):799-804. doi: 10.1136/ard.2010.139261. Epub 2011 Feb 13. Erratum in: Ann Rheum Dis. 2011 Jul;70(7):1349.

25.

Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment.

Soltész P, Kerekes G, Dér H, Szücs G, Szántó S, Kiss E, Bodolay E, Zeher M, Timár O, Szodoray P, Szegedi G, Szekanecz Z.

Autoimmun Rev. 2011 May;10(7):416-25. doi: 10.1016/j.autrev.2011.01.004. Epub 2011 Jan 31. Review.

PMID:
21281743
26.

Assessment of subclinical vascular disease associated with ankylosing spondylitis.

Bodnár N, Kerekes G, Seres I, Paragh G, Kappelmayer J, Némethné ZG, Szegedi G, Shoenfeld Y, Sipka S, Soltész P, Szekanecz Z, Szántó S.

J Rheumatol. 2011 Apr;38(4):723-9. doi: 10.3899/jrheum.100668. Epub 2011 Jan 15.

PMID:
21239756
27.

Safety and efficacy of etanercept therapy in ankylosing spondylitis patients undergoing phacoemulsification surgery.

Kemény-Beke A, Szekanecz Z, Szántó S, Bodnár N, Módis L Jr, Gesztelyi R, Zsuga J, Szodoray P, Berta A.

Rheumatology (Oxford). 2010 Nov;49(11):2220-1. doi: 10.1093/rheumatology/keq288. Epub 2010 Sep 9. No abstract available.

PMID:
20833644
28.

Biologics - beyond the joints.

Szekanecz Z, Szántó S, Szabó Z, Váncsa A, Szamosi S, Bodnár N, Szücs G.

Autoimmun Rev. 2010 Oct;9(12):820-4. doi: 10.1016/j.autrev.2010.07.011. Epub 2010 Aug 10. Review.

PMID:
20667515
29.

Increased production of asymmetric dimethylarginine (ADMA) in ankylosing spondylitis: association with other clinical and laboratory parameters.

Kemény-Beke Á, Gesztelyi R, Bodnár N, Zsuga J, Kerekes G, Zsuga M, Biri B, Kéki S, Szodoray P, Berta A, Szekanecz Z, Szántó S.

Joint Bone Spine. 2011 Mar;78(2):184-7. doi: 10.1016/j.jbspin.2010.05.009.

PMID:
20620092
30.

Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey.

Brodszky V, Péntek M, Bálint PV, Géher P, Hajdu O, Hodinka L, Horváth G, Koó E, Polgár A, Seszták M, Szántó S, Ujfalussy I, Gulácsi L.

Scand J Rheumatol. 2010 Aug;39(4):303-9. doi: 10.3109/03009740903468982.

PMID:
20166848
31.

Association of ARTS1 gene polymorphisms with ankylosing spondylitis in the Hungarian population: the rs27044 variant is associated with HLA-B*2705 subtype in Hungarian patients with ankylosing spondylitis.

Pazár B, Sáfrány E, Gergely P, Szántó S, Szekanecz Z, Poór G.

J Rheumatol. 2010 Feb;37(2):379-84. doi: 10.3899/jrheum.090806. Epub 2009 Dec 23.

PMID:
20032103
32.

The genetic background of ankylosing spondylitis.

Végvári A, Szabó Z, Szántó S, Glant TT, Mikecz K, Szekanecz Z.

Joint Bone Spine. 2009 Dec;76(6):623-8. doi: 10.1016/j.jbspin.2009.02.006. Review.

PMID:
19541528
33.

Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis.

Szodoray P, Szabó Z, Kapitány A, Gyetvai A, Lakos G, Szántó S, Szücs G, Szekanecz Z.

Autoimmun Rev. 2010 Jan;9(3):140-3. doi: 10.1016/j.autrev.2009.04.006. Epub 2009 May 7. Review.

PMID:
19427413
34.

Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment.

Brodszky V, Bálint P, Géher P, Hodinka L, Horváth G, Koó É, Péntek M, Polgár A, Seszták M, Szántó S, Ujfalussy I, Gulácsi L.

Rheumatol Int. 2009 Dec;30(2):199-205. doi: 10.1007/s00296-009-0936-1.

PMID:
19381635
35.

Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12 months: follow-up of immunopathological and clinical effects.

Szekanecz Z, Aleksza M, Antal-Szalmás P, Soltész P, Veres K, Szántó S, Szabó Z, Végvári A, Szamosi S, Lakos G, Sipka S, Szegedi G, Varga J, Szücs G.

Clin Rheumatol. 2009 Mar;28(3):347-50. doi: 10.1007/s10067-008-1062-2. Epub 2008 Dec 6.

PMID:
19067103
36.

Intracytoplasmic cytokine expression and T cell subset distribution in the peripheral blood of patients with ankylosing spondylitis.

Szántó S, Aleksza M, Mihály E, Lakos G, Szabó Z, Végvári A, Sipka S, Szekanecz Z.

J Rheumatol. 2008 Dec;35(12):2372-5. doi: 10.3899/jrheum.070839. Epub 2008 Nov 1.

PMID:
19004035
37.

Two loci on chromosome 15 control experimentally induced arthritis through the differential regulation of IL-6 and lymphocyte proliferation.

Glant TT, Szántó S, Vegvari A, Szabo Z, Kis-Toth K, Mikecz K, Adarichev VA.

J Immunol. 2008 Jul 15;181(2):1307-14.

38.

Increased arterial stiffness as the marker of vascular involvement in systemic sclerosis.

Timár O, Soltész P, Szamosi S, Dér H, Szántó S, Szekanecz Z, Szücs G.

J Rheumatol. 2008 Jul;35(7):1329-33. Epub 2008 May 15.

PMID:
18484693
39.

Anti-citrullinated protein antibodies in rheumatoid arthritis: as good as it gets?

Szekanecz Z, Soós L, Szabó Z, Fekete A, Kapitány A, Végvári A, Sipka S, Szücs G, Szántó S, Lakos G.

Clin Rev Allergy Immunol. 2008 Feb;34(1):26-31. doi: 10.1007/s12016-007-8022-5. Review.

PMID:
18270854
40.

Adenosine inhibits the release of arachidonic acid and its metabolites (AAM) in activated human peripheral mononuclear cells.

Sipka S, Kovács I, Szántó S, Szegedi G, Brugós L, Bruckner G, Szentmiklósi AJ.

Inflamm Res. 2007 Nov;56(11):468-72. doi: 10.1007/s00011-007-7102-6.

PMID:
18224288
41.

Accelerated atherosclerosis in rheumatoid arthritis.

Szekanecz Z, Kerekes G, Dér H, Sándor Z, Szabó Z, Végvári A, Simkovics E, Soós L, Szentpétery A, Besenyei T, Szücs G, Szántó S, Tamási L, Szegedi G, Shoenfeld Y, Soltész P.

Ann N Y Acad Sci. 2007 Jun;1108:349-58. Review.

PMID:
17893998
42.

Inhibition of indoleamine 2,3-dioxygenase-mediated tryptophan catabolism accelerates collagen-induced arthritis in mice.

Szántó S, Koreny T, Mikecz K, Glant TT, Szekanecz Z, Varga J.

Arthritis Res Ther. 2007;9(3):R50.

43.

Systemic sclerosis-rheumatoid arthritis overlap syndrome: a unique combination of features suggests a distinct genetic, serological and clinical entity.

Szücs G, Szekanecz Z, Zilahi E, Kapitány A, Baráth S, Szamosi S, Végvári A, Szabó Z, Szántó S, Czirják L, György Kiss C.

Rheumatology (Oxford). 2007 Jun;46(6):989-93. Epub 2007 Mar 23.

PMID:
17384178
44.

Chemokines in rheumatic diseases.

Szekanecz Z, Szücs G, Szántó S, Koch AE.

Curr Drug Targets. 2006 Jan;7(1):91-102. Review.

PMID:
16454702
45.

Visualization and in situ analysis of leukocyte trafficking into the ankle joint in a systemic murine model of rheumatoid arthritis.

Gál I, Bajnok E, Szántó S, Sarraj B, Glant TT, Mikecz K.

Arthritis Rheum. 2005 Oct;52(10):3269-78.

46.

Association of rheumatoid arthritis with HLA-DR1 and HLA-DR4 in Hungary.

Kapitány A, Zilahi E, Szántó S, Szücs G, Szabó Z, Végvári A, Rass P, Sipka S, Szegedi G, Szekanecz Z.

Ann N Y Acad Sci. 2005 Jun;1051:263-70.

PMID:
16126967
47.

CD44, but not l-selectin, is critically involved in leucocyte migration into the skin in a murine model of allergic dermatitis.

Gonda A, Gál I, Szántó S, Sarraj B, Glant TT, Hunyadi J, Mikecz K.

Exp Dermatol. 2005 Sep;14(9):700-8.

PMID:
16098130
48.

Two major interacting chromosome loci control disease susceptibility in murine model of spondyloarthropathy.

Végvári A, Szabó Z, Szántó S, Nesterovitch AB, Mikecz K, Glant TT, Adarichev VA.

J Immunol. 2005 Aug 15;175(4):2475-83.

49.

Genetic control of experimental spondylarthropathy.

Szabó Z, Szántó S, Végvári A, Szekanecz Z, Mikecz K, Glant TT.

Arthritis Rheum. 2005 Aug;52(8):2452-60.

50.

Adenosine inhibits the release of interleukin-1beta in activated human peripheral mononuclear cells.

Sipka S, Kovács I, Szántó S, Szegedi G, Brugós L, Bruckner G, József Szentmiklósi A.

Cytokine. 2005 Aug 21;31(4):258-63.

PMID:
16026998

Supplemental Content

Loading ...
Support Center